- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6756212-241-6756
- A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
- A Multicenter, Open Label Phase I / II Study of JAK2 inhibitor CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
- A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)
- Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
- Phase I study of GC1008 in patients with primary myelofibrosis (PMF), post-polycythemia vera/essential thrombocythemia related myelofibrosis (post-PV/ET MF) and essential thrombocythemia (ET)
In this episode of "Healthy Body, Healthy Mind" Dr. Mascarenhas discusses myelofibrosis - including why it's an unfamiliar term for many people, the rarity of the disease, and the age at which most people are diagnosed.
- Acute Myelogenous Leukemia—Adult
- Aplastic Anemia
- Blood Transfusion
- Chronic Myelocytic Leukemia
- Myelodysplastic Syndromes
- Primary Polycythemia
MD, New York Medical College
Residency, Internal Medicine
Rhode Island Hospital
Mount Sinai Hospital
Richard E. Rosenfeld Faculty Achievement Award
A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose
You have been asked to take part in this study because you have been diagnosed with myelofibrosis and your cancer has returned after treatment with a Janus Kinase (JAK) Inhibitor. Myelofibrosis is a type of cancer that affects the production of blood cells. The purpose o...
The purpose of this phase I study is to test the safety and tolerability of ruxolitinib at different do...
Phase I/II Study of Combination oral JAK2 tyrosine kinase inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) therapy in patients with Myelofibrosis
The purpose of this study is to find out if the drug combination of panobinostat and ruxolitinib is safe and has beneficial effects in people who have primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-M...
A Phase 2 Pilot Trial of Ruxolitinib combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
The purpose of this study is to find out if the drug Ruxolitnib combined with Danazol is safe and has beneficial effects in people who are diagnosed with Primary Myelofibrosis (PMF) or Post-Essential Thromobocythemia Myelofibrosis (PET MF) or Post-Polycythemia Vera Myelofibrosis ...
The purpose of this study is to gather information on whether PRM-151 has an effect on your myelofibrosis (MF) disease, whether it is safe in patients wit...
Open label study of single agent oral RG7388 in patients with polycythemia vera and essential thrombocythemia, with pilot feasibility study in combination with pegylated interferon alfa 2a
The research looks at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and pV causes too many platelets and red blood cells to be made. Platelets are particles which circulate ...
An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia-Myelofibrosis (PET-MF)
The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called INCB039110. An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. The purpose of this research study is ...
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Mascarenhas during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Incyte Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.